Download Image
    
Share
  
Post
Inosine Pranobex for COVID-19
2 studies with 414 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon
Inosine Pranobex
Inosine Pran..
Significantly lower risk for recovery.
2 studies from 2 independent teams in 2 countries show significant benefit.
COVID-19 Inosine Pranobex studies. Apr 2026. c19early.org
0 0.5 1 1.5+ All studies 29% Mortality 46% RCTs 27% Early 29% Favorsinosine pranobex Favorscontrol
Inosine pranobex is an orally administered small-molecule immunomodulator with broad antiviral activity. It enhances natural killer cell cytotoxicity and T-lymphocyte function and promotes Th1-type cytokine responses, thereby augmenting host antiviral defenses. Inosine Pranobex was adopted in 1 country. Recent:
Jayanthi
Veselý.
Apr 29
 Covid Analysis Meta-analysis of inosine pranobex studies
Meta-analysis of inosine pranobex studies
Mar 31
 Veselý et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2026.108519 Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry
46% lower mortality (p=0.11). Retrospective 67,841 inosine pranobex recipients matched 1:2 with 135,682 controls from the Czech national registry, showing significantly reduced COVID-19 mortality with treatment. Negative control outcome analyses (non-COVID mortality,..
Sep 16
2022
 Jayanthi et al., Advanced Therapeutics, doi:10.1002/adtp.202200159 Efficacy and Safety of Inosine Pranobex in COVID‐19 Patients: A Multicenter Phase 3 Randomized Double‐Blind, Placebo‐Controlled Trial
27% improved recovery (p=0.003) and 33% greater improvement (p=0.0005). RCT 416 mild-to-moderate COVID-19 patients (both hospitalized and non-hospitalized) showing improved recovery with inosine pranobex.